Precision Biologics Reveals Potent Tumor-Erasing Cancer Drug Data

BETHESDA, MD – February 13, 2026 – In a development that could signal a new frontier in the war on cancer, Maryland-based Precision Biologics is set to unveil compelling preclinical data for a novel cancer therapy that has demonstrated the ability to completely eradicate solid tumors in animal models with minimal side effects. The full data for the new antibody-drug conjugate (ADC), known as PB-223, will be presented for the first time in a keynote address at the 6th ACE Drug Discovery Summit in London this week.

The announcement has generated significant buzz within the oncology community, as the drug targets a wide array of solid tumors—a notoriously difficult class of cancers to treat. The data, according to the company, showcases not just efficacy but a high degree of precision, potentially offering a powerful new weapon for doctors and a beacon of hope for patients.

A Highly Targeted Molecular Warhead

At the heart of PB-223's promise is its design as an antibody-drug conjugate, a class of therapies often described as "biological smart bombs." ADCs work by linking a potent cancer-killing chemical (the payload) to a monoclonal antibody (the guidance system). This antibody is engineered to seek out and bind exclusively to a specific protein or marker, known as an antigen, that is abundant on the surface of cancer cells but largely absent from healthy ones. This targeted delivery system allows the ADC to unleash its toxic payload directly inside the tumor, maximizing its destructive power while minimizing the collateral damage to healthy tissue that causes the debilitating side effects associated with traditional chemotherapy.

What sets PB-223 apart is its unique target: a specific type of sugar molecule called truncated core 2 O-glycans. These aberrant glycans are a hallmark of cellular malfunction and are found on the surface of a broad variety of human solid tumors, including notoriously aggressive cancers. Crucially, they are not present on healthy adult tissues. This specificity is the key to the drug's potential.

In a statement ahead of the summit, Precision Biologics CEO Dr. Philip M. Arlen highlighted this advantage. "The exquisite sensitivity and specificity of our recently developed mAb enables maximum anti-tumor response to our PB-223 ADC with minimal toxicity in the preclinical animal studies," he said. "The target is found on a broad variety of human solid tumors but not on healthy tissue, suggesting a strong rationale to move this drug into clinical trials."

The preclinical results to be presented in London reportedly come from studies using animal xenograft models, where human tumors are implanted in mice. In these studies, PB-223 achieved what many researchers consider a holy grail of oncology research: complete tumor eradication. Post-treatment analysis of blood and tissue samples confirmed the company's claims of minimal toxicity.

Entering the High-Stakes ADC Arena

While the data for PB-223 is new, Precision Biologics is stepping into one of the hottest and most competitive sectors in the pharmaceutical industry. The ADC market has exploded in recent years, with global valuations projected to surpass $30 billion by the early 2030s. This boom is fueled by a string of successful drug approvals and a growing demand for more precise, less toxic cancer treatments.

The field is dominated by pharmaceutical giants. Pfizer's $43 billion acquisition of ADC pioneer Seagen, and the multibillion-dollar success of Enhertu, a drug co-developed by Daiichi Sankyo and AstraZeneca, underscore the immense commercial and clinical potential of this technology. Enhertu alone generated over $3.7 billion in 2024 and has gained approvals for treating a range of HER2-positive solid tumors, setting a high bar for new entrants.

For a smaller, privately-held company like Precision Biologics, competing against behemoths like Roche, AbbVie, and Bristol Myers Squibb is a monumental task. Success will depend not just on strong clinical data but on demonstrating a clear advantage over the dozens of other ADCs already on the market or in late-stage development. PB-223's unique target—the truncated core 2 O-glycans—could provide that crucial edge. While many existing ADCs target well-known proteins like HER2 or TROP-2, exploring novel targets like aberrant glycans represents a new strategic front in the ADC race, potentially unlocking treatment options for cancers that don't express the more common antigens.

"We're excited to discuss PB-223 ADC with the scientific community, to share compelling preclinical data with several human tumor types," Arlen stated, emphasizing the results showing "complete tumor eradication with minimal toxicity." This presentation in London, which follows preliminary poster displays at earlier scientific meetings, marks the company's formal introduction of its complete data set to the world.

The Long Road from Preclinical Promise to Patient Care

The excitement surrounding the preclinical success of PB-223 is palpable, but it is also tempered by the harsh realities of drug development. A promising result in animal models is a critical first step, but it is far from a guarantee of success in humans. The path from the lab to the pharmacy is a long, arduous, and expensive journey fraught with risk.

The next major hurdle for Precision Biologics will be to secure approval from regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to begin human testing. This requires submitting a comprehensive Investigational New Drug (IND) application, a massive dossier containing all preclinical safety, toxicity, and manufacturing data. If approved, PB-223 would enter Phase 1 clinical trials, where the drug is given to a small number of patients primarily to assess its safety, identify side effects, and determine a safe dosage range.

Only if Phase 1 is successful can the company proceed to larger Phase 2 and Phase 3 trials, which are designed to evaluate the drug's effectiveness against cancer and compare it to existing treatments. This multi-year, multi-phase process is where the vast majority of promising drug candidates fail, either due to unexpected toxicity or a lack of efficacy in human patients.

Furthermore, developing and manufacturing a complex biologic like an ADC is a highly specialized and costly endeavor. For a private biotech, securing the substantial funding required to navigate years of clinical trials and scale up production represents a significant challenge. Despite these hurdles, the strength of the preclinical data provides a powerful foundation. The claim of complete tumor clearance with low toxicity, if it can be replicated in even a fraction of human patients, would represent a major breakthrough and undoubtedly attract significant interest from both investors and larger pharmaceutical partners looking to bolster their oncology pipelines. The journey for PB-223 is just beginning, but its first steps have been incredibly promising.